 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NTN Buzztime, Inc. NTN or the Company NYSE American: NTN in connection with the Companys proposed merger with privately-held biopharmaceutical company Brooklyn ImmunoTherapeutics LLC Brooklyn ImmunoTherapeutics. Under the terms of the merger agreement, NTN will combine with Brooklyn ImmunoTherapeutics and cease to exist, and the combined company will continue to operate under the Brooklyn ImmunoTherapeutics name. At close of the transaction, current Brooklyn ImmunoTherapeutics equity holders will own 94.08 of the surviving entity, leaving shareholders of NTN with a mere 5.92 ownership stake in the newly combined company. 